MetaVia (MTVA) investor relations material

Executive summary

• Focused on developing novel pharmaceuticals for cardiometabolic diseases, with two main programs: vanoglipel (MASH, T2DM) and DA-1726 (obesity, MASH).

• Achieved key clinical milestone with all active patients in Phase 1 Part 3 study of DA-1726 reaching highest planned dose levels (48 mg and 64 mg).

• Presented promising clinical data for DA-1726, showing up to 9.1% mean body weight reduction and improvements in liver biomarkers, with new data presented at major scientific conferences.

• Advanced vanoglipel as a differentiated combination therapy for metabolic and liver diseases, with preclinical data supporting anti-fibrotic potential.

• Four legacy programs are being considered for out-licensing or divestiture.

Financial highlights

• Net loss of $5.3 million for Q2 2026, compared to $4.0 million in Q2 2025; net loss of $9.1 million for the six months ended June 30, 2026, versus $7.7 million in the prior year period.

• Total operating expenses increased 25.2% year-over-year for Q2 2026, mainly due to higher R&D expenses, which rose to $3.5 million (up 49.9% YoY), driven by DA-1726 clinical trial activities.

• General and administrative expenses were $1.9 million for Q2 2026, slightly down from $2.0 million in Q2 2025.

• Cash and cash equivalents were $12.6 million as of June 30, 2026, up from $10.3 million at year-end 2025.

• Accumulated deficit reached $158.0 million as of June 30, 2026.

Outlook and guidance

• Expect continued net losses and negative cash flows from operations due to ongoing clinical trials.

• Data readouts for vanoglipel and DA-1726 planned for Q4 2026, including topline 16-week data from DA-1726 Phase 1 Part 3 study.

• End-of-Phase 2 FDA meeting for vanoglipel combination therapy planned for the second half of 2026.

• Cash position expected to fund operations through 2027.

• Substantial doubt exists about the ability to continue as a going concern within one year without additional capital.